ProShare Advisors
ATXS

ProShare Advisors’s Astria Therapeutics ATXS Stock Holding History

ProShare Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,869
Closed -$58.3K – 2013
2025
Q2 		$58.3K Sell
10,869
-1,694
-13% -$8.21K ﹤0.01% 1974
2025
Q1 		$67.1K Sell
12,563
-3,143
-20% -$22K ﹤0.01% 1914
2024
Q4 		$140K Buy
+15,706
New +$167K ﹤0.01% 1992

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ProShare Advisors's ATXS Position: Q3 2025 in Review

ProShare Advisors sold out of Astria Therapeutics (ATXS) in Q3 2025, closing a stake of 10,869 shares — an estimated $58.3K sold.

ProShare Advisors first reported a position in ATXS in Q4 2024 and held it in 3 quarters. The position peaked at $140K in Q4 2024. 115 funds tracked by Wall St. Rank hold ATXS as of Q3 2025.

  • ProShare Advisors reported no remaining Astria Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ProShare Advisors sold 10,869 Astria Therapeutics shares in Q3 2025, an estimated $58.3K.
  • ProShare Advisors first reported a position in Astria Therapeutics in Q4 2024 and held it in 3 quarters.
  • ProShare Advisors's Astria Therapeutics position peaked at $140K in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2025.

Based on ProShare Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.